Loading...

Poly Medicure

NSEI:POLYMED
Snowflake Description

Flawless balance sheet second-rate dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
POLYMED
NSEI
₹17B
Market Cap
  1. Home
  2. IN
  3. Healthcare
Company description

Poly Medicure Limited manufactures and sells medical devices in India and internationally. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
POLYMED Share Price and Events
7 Day Returns
0.1%
NSEI:POLYMED
0.1%
IN Medical Equipment
4.1%
IN Market
1 Year Returns
-17.1%
NSEI:POLYMED
-23%
IN Medical Equipment
0.1%
IN Market
POLYMED Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Poly Medicure (POLYMED) 0.1% -2.6% -7.3% -17.1% 10.6% 71.5%
IN Medical Equipment 0.1% -4.1% -8.9% -23% 7.4% -8.4%
IN Market 4.1% -0.5% 7.6% 0.1% 35.2% 47.8%
1 Year Return vs Industry and Market
  • POLYMED outperformed the Medical Equipment industry which returned -23% over the past year.
  • POLYMED underperformed the Market in India which returned 0.1% over the past year.
Price Volatility
POLYMED
Industry
5yr Volatility vs Market

POLYMED Value

 Is Poly Medicure undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Poly Medicure to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Poly Medicure.

NSEI:POLYMED Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 15.8%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:POLYMED
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.89
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.894 (1 + (1- 35%) (7.91%))
0.959
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.959 * 8.6%)
15.8%

Discounted Cash Flow Calculation for NSEI:POLYMED using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Poly Medicure is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:POLYMED DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 15.8%)
2019 200.37 Est @ 11.65% 173.03
2020 221.24 Est @ 10.42% 164.99
2021 242.39 Est @ 9.56% 156.09
2022 264.09 Est @ 8.95% 146.86
2023 286.63 Est @ 8.53% 137.64
2024 310.24 Est @ 8.24% 128.65
2025 335.16 Est @ 8.03% 120.02
2026 361.60 Est @ 7.89% 111.82
2027 389.75 Est @ 7.79% 104.08
2028 419.82 Est @ 7.72% 96.81
Present value of next 10 years cash flows ₹1,339.99
NSEI:POLYMED DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹419.82 × (1 + 7.55%) ÷ (15.8% – 7.55%)
₹5,472.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹5,472.03 ÷ (1 + 15.8%)10
₹1,261.86
NSEI:POLYMED Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹1,339.99 + ₹1,261.86
₹2,601.85
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹2,601.85 / 88.24
₹29.49
NSEI:POLYMED Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:POLYMED represents 0.99541x of BSE:531768
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99541x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 29.49 x 0.99541
₹29.35
Value per share (INR) From above. ₹29.35
Current discount Discount to share price of ₹195.10
= -1 x (₹195.10 - ₹29.35) / ₹29.35
-564.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Poly Medicure is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Poly Medicure's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Poly Medicure's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:POLYMED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹7.41
BSE:531768 Share Price ** BSE (2019-05-24) in INR ₹196
India Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 19.66x
India Market PE Ratio Median Figure of 2,781 Publicly-Listed Companies 15.78x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Poly Medicure.

NSEI:POLYMED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:531768 Share Price ÷ EPS (both in INR)

= 196 ÷ 7.41

26.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Poly Medicure is overvalued based on earnings compared to the IN Medical Equipment industry average.
  • Poly Medicure is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Poly Medicure's expected growth come at a high price?
Raw Data
NSEI:POLYMED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 26.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Asia Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 1.11x
India Market PEG Ratio Median Figure of 559 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Poly Medicure, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Poly Medicure's assets?
Raw Data
NSEI:POLYMED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹43.21
BSE:531768 Share Price * BSE (2019-05-24) in INR ₹196
India Medical Equipment Industry PB Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 0.73x
India Market PB Ratio Median Figure of 3,644 Publicly-Listed Companies 1.06x
NSEI:POLYMED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:531768 Share Price ÷ Book Value per Share (both in INR)

= 196 ÷ 43.21

4.54x

* Primary Listing of Poly Medicure.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Poly Medicure is overvalued based on assets compared to the IN Medical Equipment industry average.
X
Value checks
We assess Poly Medicure's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Poly Medicure has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

POLYMED Future Performance

 How is Poly Medicure expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Poly Medicure expected to grow at an attractive rate?
  • Unable to compare Poly Medicure's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Poly Medicure's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Poly Medicure's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:POLYMED Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 19%
Asia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 16.9%
India Market Revenue Growth Rate Market Cap Weighted Average 10.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:POLYMED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:POLYMED Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-03-31 6,865 737 1
NSEI:POLYMED Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 6,108 654
2018-03-31 5,204 749 706
2017-03-31 4,550 561 551

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Poly Medicure is high growth as no earnings estimate data is available.
  • Unable to determine if Poly Medicure is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:POLYMED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Poly Medicure Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:POLYMED Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-03-31 8.36 8.36 8.36 1.00
NSEI:POLYMED Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 7.41
2018-03-31 8.00
2017-03-31 6.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Poly Medicure will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Poly Medicure's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Poly Medicure has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

POLYMED Past Performance

  How has Poly Medicure performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Poly Medicure's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Poly Medicure's year on year earnings growth rate has been positive over the past 5 years.
  • Poly Medicure's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Poly Medicure's 1-year earnings growth is negative, it can't be compared to the IN Medical Equipment industry average.
Earnings and Revenue History
Poly Medicure's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Poly Medicure Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:POLYMED Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 6,108.25 653.99 1,166.07 101.49
2018-03-31 5,204.17 705.94 1,035.46 100.48
2017-03-31 4,550.06 551.25 930.87 90.34
2016-03-31 4,122.57 482.68 791.25 87.11
2015-03-31 3,903.47 623.23 686.62 84.67
2014-03-31 3,222.48 450.94 783.56 59.24
2013-03-31 2,597.54 242.30 589.92 39.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Poly Medicure has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Poly Medicure used its assets more efficiently than the IN Medical Equipment industry average last year based on Return on Assets.
  • Poly Medicure's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Poly Medicure's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Poly Medicure has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

POLYMED Health

 How is Poly Medicure's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Poly Medicure's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Poly Medicure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Poly Medicure's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Poly Medicure's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Poly Medicure Company Filings, last reported 1 month ago.

NSEI:POLYMED Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3,813.70 1,368.54 602.76
2018-03-31 3,382.95 1,328.64 308.59
2017-03-31 2,715.38 1,007.38 225.18
2016-03-31 2,286.29 824.63 217.26
2015-03-31 1,961.75 788.06 199.83
2014-03-31 1,464.58 669.64 138.25
2013-03-31 1,124.57 487.39 7.98
  • Poly Medicure's level of debt (35.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (45.7% vs 35.9% today).
  • Debt is well covered by operating cash flow (54.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 7.8x coverage).
X
Financial health checks
We assess Poly Medicure's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Poly Medicure has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

POLYMED Dividends

 What is Poly Medicure's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.02%
Current annual income from Poly Medicure dividends.
If you bought ₹2,000 of Poly Medicure shares you are expected to receive ₹20 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Poly Medicure's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.53%).
  • Poly Medicure's dividend is below the markets top 25% of dividend payers in India (1.98%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:POLYMED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Asia Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 13 Stocks 1.5%
India Market Average Dividend Yield Market Cap Weighted Average of 1407 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:POLYMED Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2020-03-31
NSEI:POLYMED Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-10 2.000 1.025
2018-05-10 2.000 0.916
2017-05-19 1.500 0.623
2017-02-06 1.250 0.475
2016-11-10 0.750 0.381
2016-09-06 1.500 0.766
2016-05-16 1.500 0.782
2016-03-10 2.500 1.751
2015-07-31 1.250 0.712
2015-05-04 1.250 0.521
2014-07-30 1.000 0.489
2014-05-15 1.000 0.868
2013-09-03 0.500 0.583
2013-05-13 0.500 0.786
2012-10-01 0.375 0.725
2011-09-08 0.375 1.127
2010-08-02 0.313 0.952
2010-05-17 0.313 1.582
2009-06-01 0.156 1.829

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Poly Medicure's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Poly Medicure's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Poly Medicure afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Poly Medicure has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

POLYMED Management

 What is the CEO of Poly Medicure's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Himanshu Baid
COMPENSATION ₹41,425,000
AGE 50
TENURE AS CEO 23.7 years
CEO Bio

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect to manufacturing facility of Philips Communications Industry AG. Nurenberg, Germany. He served as the Chief Executive of Marketing at Polycon International Limited and looked after the day to day techno-commercial affairs of Polycon International Limited. Mr. Baid serves as a Director of Poly Medicure Limited. He holds Engineering degree.

CEO Compensation
  • Himanshu's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
  • Himanshu's remuneration is higher than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Poly Medicure management team in years:

4
Average Tenure
47
Average Age
  • The tenure for the Poly Medicure management team is about average.
Management Team

Himanshu Baid

TITLE
CEO, MD & Director
COMPENSATION
₹41M
AGE
50
TENURE
23.7 yrs

Jugal Baid

TITLE
Founder & Non Executive Director
COMPENSATION
₹975K
AGE
76

Jas Karan Oswal

TITLE
Chief Financial Officer
COMPENSATION
₹4M
TENURE
4 yrs

P. Rastogi

TITLE
Assistant Vice President of Finance & Accounts
AGE
47

Hemant Bhalla

TITLE
Vice President of Sales & Marketing
AGE
59

Rishi Baid

TITLE
Executive Director
COMPENSATION
₹41M
AGE
46

Vishal Baid

TITLE
President of Corporate Sales & Marketing
AGE
44

Avinash Chandra

TITLE
Company Secretary
COMPENSATION
₹747K
TENURE
4 yrs

Amitabh Sagar

TITLE
C.H.R.O. (HR & Admin)
AGE
46
Board of Directors Tenure

Average tenure and age of the Poly Medicure board of directors in years:

7
Average Tenure
59
Average Age
  • The tenure for the Poly Medicure board of directors is about average.
Board of Directors

Devendra Mehta

TITLE
Chairman
COMPENSATION
₹1,000K
AGE
81

Himanshu Baid

TITLE
CEO, MD & Director
COMPENSATION
₹41M
AGE
50

Jugal Baid

TITLE
Founder & Non Executive Director
COMPENSATION
₹975K
AGE
76
TENURE
24.2 yrs

Rishi Baid

TITLE
Executive Director
COMPENSATION
₹41M
AGE
46
TENURE
21.8 yrs

Prakash Surana

TITLE
Non-Executive Independent Director
COMPENSATION
₹1M
AGE
71
TENURE
21.7 yrs

Shailendra Mehta

TITLE
Non-Executive Independent Director
COMPENSATION
₹1M
AGE
59
TENURE
7 yrs

Mukulika Baid

TITLE
Non-Executive Director
COMPENSATION
₹950K
AGE
68
TENURE
4.8 yrs

Sandeep Bhargava

TITLE
Non-Executive Independent Director
COMPENSATION
₹900K
AGE
51
TENURE
2.3 yrs

Alessandro Balboni

TITLE
Additional Non-Executive Director
AGE
57
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Poly Medicure's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Poly Medicure has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

POLYMED News

Simply Wall St News

Does Poly Medicure Limited's (NSE:POLYMED) CEO Pay Compare Well With Peers?

At the time of writing our data says that Poly Medicure Limited has a market cap of ₹17b, and is paying total annual CEO compensation of ₹41m. … Thus we can conclude that Himanshu Baid receives more in total compensation than the median of a group of companies in the same market, and of similar size to Poly Medicure Limited. … We compared the total CEO remuneration paid by Poly Medicure Limited, and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

Investors Who Bought Poly Medicure (NSE:POLYMED) Shares Five Years Ago Are Now Up 80%

For example, the Poly Medicure Limited (NSE:POLYMED) share price is 80% higher than it was five years ago, which is more than the market average. … During five years of share price growth, Poly Medicure achieved compound earnings per share (EPS) growth of 24% per year. … This EPS growth is higher than the 13% average annual increase in the share price.

Simply Wall St -

Why Poly Medicure Limited (NSE:POLYMED) Could Have A Place In Your Portfolio

Poly Medicure Limited (NSE:POLYMED) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … Below, I've touched on some key aspects you should know on a high level

Simply Wall St -

Can Poly Medicure Limited (NSE:POLYMED) Maintain Its Strong Returns?

Our data shows Poly Medicure has a return on equity of 21% for the last year. … That means that for every ₹1 worth of shareholders' equity, it generated ₹0.21 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Poly Medicure Limited’s (NSE:POLYMED) 21% ROCE Any Good?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Understanding Return On Capital Employed (ROCE). … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St -

With 28% Earnings Growth, Did Poly Medicure Limited (NSE:POLYMED) Outperform The Industry?

When Poly Medicure Limited (NSE:POLYMED) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happening in the industry. … Understanding how Poly Medicure performed requires a benchmark rather than trying to assess a standalone number at one point in time. … Were POLYMED's earnings stronger than its past performances and the industry.

Simply Wall St -

Should You Be Tempted To Sell Poly Medicure Limited (NSE:POLYMED) At Its Current PE Ratio?

Poly Medicure Limited (NSE:POLYMED) is currently trading at a trailing P/E of 31.1x, which is higher than the industry average of 20x. … While POLYMED might seem like a stock to avoid or sell if you own it, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions. … Check out our latest analysis for Poly Medicure

Simply Wall St -

Poly Medicure Limited (NSE:POLYMED): The Return Story

Your equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … You need to pay attention to this because your return on investment is linked to dividends and internal investments to improve the business, which can only occur if the company is expected to produce adequate earnings with the capital that has been provided. … To understand Poly Medicure’s capital returns we will look at a useful metric called return on capital employed.

Simply Wall St -

Poly Medicure Limited (NSE:POLYMED): Is Now The Time To Bet On Healthcare?

which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities … healthcare equipment providers are faced with particularly difficult and interdependent challenges … Therefore, care delivery approaches that are holistic and technology-enabled are more likely to result in positive outcomes in the long run.

Simply Wall St -

Does Poly Medicure Limited's (NSE:POLYMED) PE Ratio Signal A Selling Opportunity?

POLYMED is priced at a steep multiple of 27.32x based on its prior year’s earnings,. … considerably outstripping the 21.99x average multiple of the IN Medical Equipment? … But can investors make a closing judgement of the company’s value based on this bigger multiple.

Simply Wall St -

POLYMED Company Info

Description

Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, needle free connectors, three way stop cocks, I.V. infusion sets, I.V. flow regulators, extension lines, Y-type infusion and transfusion sets, T-type extension sets, injection stoppers, obturators, luer lock injection sites, and safety winged infusion sets; and central venous catheters and CVP manometers. The company also provides anesthesia devices, including suction and oxygen catheters, oxygen and aerosol therapy masks, nasocath cannulas, catheter mounts, guedel airways, respiratory exercisers, endotracheal and tracheostomy tubes, spinal needles, and fixed concentration masks; gastroenterology products, such as Ryle’s and Levin’s tubes, infant feeding tubes, feeding bags, T tubes, stomach tubes, and umbilical catheters; and urology devices comprising urine collection bags, measured volume meters, urine drainage catheters, TUR sets, Foley balloon catheters, and irrigation sets. In addition, it offers blood administration sets, blood bag systems, transfusion pump sets, blood bags with safety device and sampling bags, CPD-SAGM-TOTM bag systems, top and bottom extraction bag systems, ACD bags, blood collection tubes and needles, and safety blood collection sets; surgery and wound drainage devices, such as redon drains, thoracic drainage catheters, abdominal drainage sets, under water seal drainage systems and bottles, yankauer suction sets, yankaur suction handles, colostomy bags, closed wound suction units, and high pressure vacuum bottles with extension tubes. Further, it provides dialysis products, including fistula needles, haemodialysis catheters, peritoneal dialysis transfusion sets, and blood lines; and mucus extractors, umbilical cord clamps, insulin syringes, sputum collectors, and dry brushes. Poly Medicure Limited was founded in 1995 and is based in New Delhi, India.

Details
Name: Poly Medicure Limited
POLYMED
Exchange: NSEI
Founded: 1995
₹17,294,438,280
88,236,930
Website: http://www.polymedicure.com
Address: Poly Medicure Limited
232B, Okhla Industrial Estate,
3rd Floor,
New Delhi,
Delhi, 110020,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 531768 Equity Shares Mumbai Stock Exchange IN INR 19. Nov 2004
NSEI POLYMED Equity Shares National Stock Exchange of India IN INR 19. Nov 2004
BSE 531768 INR5 Mumbai Stock Exchange IN INR 02. Feb 2015
NSEI POLYMED INR5 National Stock Exchange of India IN INR 02. Feb 2015
Number of employees
Current staff
Staff numbers
1,926
Poly Medicure employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 12:56
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.